A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Thomas E. Stinchcombe; Daniel S. Bradford; Thomas A. Hensing; Renato V. LaRocca; Mansoor Saleh; Tracey Evans; Kamal Bakri; Mark A. Socinski

doi:10.3109/07357900903286958

A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Thomas E. Stinchcombe, Daniel S. Bradford, Thomas A. Hensing, Renato V. LaRocca, Mansoor Saleh, Tracey Evans, Kamal Bakri, Mark A. Socinski

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

Original language	English
Pages (from-to)	208-215
Number of pages	8
Journal	Cancer Investigation
Volume	28
Issue number	2
DOIs	https://doi.org/10.3109/07357900903286958
Publication status	Published - 2010
Externally published	Yes

Keywords

Clinical trial
Epidermal growth factor receptor (EGFR)
First-line therapy
Lung cancer
Platinum-based

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357900903286958

Cite this

@article{e84853c6da4941f58d6013917e98f47a,

title = "A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer",

abstract = "Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.",

keywords = "Clinical trial, Epidermal growth factor receptor (EGFR), First-line therapy, Lung cancer, Platinum-based",

author = "Stinchcombe, {Thomas E.} and Bradford, {Daniel S.} and Hensing, {Thomas A.} and LaRocca, {Renato V.} and Mansoor Saleh and Tracey Evans and Kamal Bakri and Socinski, {Mark A.}",

year = "2010",

doi = "10.3109/07357900903286958",

language = "English",

volume = "28",

pages = "208--215",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

AU - Stinchcombe, Thomas E.

AU - Bradford, Daniel S.

AU - Hensing, Thomas A.

AU - LaRocca, Renato V.

AU - Saleh, Mansoor

AU - Evans, Tracey

AU - Bakri, Kamal

AU - Socinski, Mark A.

PY - 2010

Y1 - 2010

N2 - Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

AB - Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

KW - Clinical trial

KW - Epidermal growth factor receptor (EGFR)

KW - First-line therapy

KW - Lung cancer

KW - Platinum-based

UR - http://www.scopus.com/inward/record.url?scp=77149127367&partnerID=8YFLogxK

U2 - 10.3109/07357900903286958

DO - 10.3109/07357900903286958

M3 - Article

C2 - 19916742

AN - SCOPUS:77149127367

SN - 0735-7907

VL - 28

SP - 208

EP - 215

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this